By Nascent Biotech Posted November 9, 2019 In BJCR-104(10) copy2019-11-092019-11-09http://www.nascentbiotech.com/wp-content/uploads/2015/06/nascent-logo-horiz-300.pngNascent Biotechhttp://www.nascentbiotech.com/wp-content/uploads/2015/06/nascent-logo-horiz-300.png200px200px 0 BJCR-104(10) copy Recent PostsNascent Biotech to Begin Phase II Clinical Trials for Brain CancerBenzinga: Why NBIO is a Biotech Bargain Basement Deal with Underappreciated PotentialJournal of Clinical Oncology: Phase 1 study of pritumumab in brain cancer.Nascent Biotech Regains Worldwide Rights for Pritumumab
